Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154178 | 0.82 | GSK3B (0.48) | DNMT3AGSK3BMAPTNLRP3LMNA | |
| SCHEMBL8405902 | 0.79 | HTR1A (0.44) | KMT2ALMNA | |
| SCHEMBL8322241 | 0.79 | HTR1A (0.44) | KMT2ALMNA | |
| SCHEMBL1153717 | 0.79 | AKR1C3 (0.57) | AKR1C3KMT2ADNMT3ALRRK2HDAC1 | |
| SCHEMBL1154997 | 0.78 | DNMT3A (0.45) | AKR1C3DNMT3AHDAC1HDAC6MAPT | |
| SCHEMBL1153970 | 0.78 | PPARA (0.59) | AKR1C3KMT2ADNMT3AHDAC1HDAC6 | |
| SCHEMBL11561500 | 0.77 | LRRK2 (0.63) | AKR1C3KMT2ALRRK2 | |
| SCHEMBL1152424 | 0.76 | LRRK2 (0.57) | AKR1C3KMT2ADNMT3ALRRK2MAPT | |
| SCHEMBL1154735 | 0.76 | DNMT3A (0.60) | AKR1C3KMT2ADNMT3AHDAC1HDAC6 | |
| SCHEMBL1153664 | 0.76 | PTGER4 (0.59) | AKR1C3KMT2ADNMT3ALRRK2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | claimed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | claimed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | claimed |
| EP-2215065-A1 | CCR10 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | claimed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| EP-2215065-A1 | CCR10 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039851-A1 | CCR10 ANTAGONISTS | CCR10, CCR1, CCR4 | AKR1C3 680/4885KMT2A 3531/4885DNMT3A 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.